Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method
Recruiting
This study formulates consensus agreement on clinical key elements related to prostate cancer care that are critical for standardization and global reported using a robust Delphi technique, completely remote and electronic. The goal of this survey study is to have a panel of specialty-specific experts create a consensus agreement on a minimum set of key data elements for use in standardized reports. These recommendations would be used to develop standardized methods to report key data in electro... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/21/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Investigation of Surgical Sectioning of the Filum Terminale in Treating Occult Tethered Cord Syndrome Patients
Recruiting
The investigators hypothesize that surgical release of the filum terminale (strand of fibrous tissue at the end of the spinal cord) is a more efficacious treatment option for symptomatic relief than medical management in subjects with Occult Tethered Cord Syndrome (OTCS) and that the risks do not outweigh the benefit profile.
Gender:
ALL
Ages:
Between 2 years and 80 years
Trial Updated:
05/21/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Tethered Cord, Tethered Cord Syndrome, Occult Spina Bifida, Spina Bifida Occulta
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
Recruiting
To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota +3 locations
Conditions: Gastrostomy, Gastric, GastroEsophageal Cancer
Using the Multiphase Optimization Strategy to Adapt Cognitive Processing Therapy
Recruiting
Cognitive Processing Therapy (CPT) consists of discrete therapeutic components that are delivered across 12 sessions, but most Veterans never reach session 12, and those who drop out receive only 4 sessions on average. Veterans drop out because of time constraints, logistics, and lack of perceived benefit. Unfortunately, Veterans who drop out prematurely may never receive the most effective components of CPT and continue to experience symptom-related distress and numerous other negative outcomes... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan +2 locations
Conditions: Stress Disorders, Post-Traumatic
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
Recruiting
In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse. Patients will receive up to about 9 cycles of treatment with Tag and have a bone marrow biopsy after cycle 4 and about 1 year after HCT.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania +1 locations
Conditions: Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Recruiting
This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic syndrome (MDS/AML), and acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL). The names of the study drugs involved in this study are below. Please note this is a list for the study as a whole, participants will receive drugs according to d... Read More
Gender:
ALL
Ages:
Between 1 year and 40 years
Trial Updated:
05/21/2025
Locations: University of California San Francisco-Benioff Children's Hospital, San Francisco, California +4 locations
Conditions: Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
Recruiting
The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can help people with HER2 (human epidermal growth factor receptor 2) positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: HER2-positive Breast Cancer
Inflammatory and Glutamatergic Mechanisms of Sustained Threat in Adolescents With Depression
Recruiting
Despite the prevalence and significant public health concern over depression among adolescents, up to 40% of depressed adolescents do not respond to first-line antidepressants (herein termed treatment non-response, TNR). The goal of this project is to recruit and assess 160 treatment-seeking depressed adolescents and test whether acute stress impacts peripheral levels of inflammation and downstream levels of glutamate in corticolimbic regions previously associated with depression, whether these... Read More
Gender:
ALL
Ages:
Between 14 years and 21 years
Trial Updated:
05/21/2025
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Depression in Adolescence
Behavioral Intervention to Reduce Stress Among Black Gender Minority Women
Recruiting
The research objectives of this study are to first, develop a culturally informed community-based intervention with guidance from community members (via focus groups and theater testing) to reduce the effect of chronic stigma exposure on psychological distress symptoms (PTS and depressive symptoms) among transgender women. Second, the research team will conduct a proof-of-concept trial to determine the feasibility and preliminary efficacy of the resulting intervention.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
05/21/2025
Locations: Emory University School of Nursing, Atlanta, Georgia
Conditions: Psychological Distress, Stigma, Social
Ethnic Microaggressions and Smoking Behaviors Among Latinx Adults
Recruiting
The purpose of this study is to examine whether microaggressions relate to multimodal facets of smoking behavior, subjective withdrawal, and urge/craving. Additionally, the second aim is to examine whether smoking deprivation moderates the relation between microaggressions and multiple facets of smoking behavior, subjective withdrawal, and urge/craving.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: RESTORE Laboratory: Research on Emotion, Substance Treatment Outcomes, and Racial Equity, Houston, Texas
Conditions: Smoking, Discrimination, Racial
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Recruiting
This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida +7 locations
Conditions: Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
Recruiting
The purpose of the study is to determine the safety of combining the drugs gemtuzumab ozogamicin (GO) with CPX-351 in order to treat the disease, as well as to find the maximum tolerated dose level and recommended Phase 2 dose level of GO with a fixed dose of CPX-351.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Acute Myeloid Leukemia